Search research articles
Contact Us
Filters
Showing results (1-10 of 46) with videos related to
Page
of 5
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 29, 2022
Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: No
Emma C Tallantyre
Journal of Neurology
|
November 2, 2018
Nerve sheath tumours
James A Robertson, Emma C Tallantyre
Practical Neurology
|
May 8, 2021
MRI: how to understand it
Claire Louise MacIver, Sian Ebden, Emma C Tallantyre
Current Opinion in Allergy and Clinical Immunology
|
October 10, 2018
Secondary antibody deficiency in neurology
Emma C Tallantyre, Neil P Robertson, Stephen Jolles
Practical Neurology
|
November 13, 2015
How to run a multiple sclerosis relapse clinic
Emma C Tallantyre, Mark Wardle, Neil P Robertson
JAMA Neurology
|
October 15, 2019
Cautious Interpretation of Observational Data-Reply
Katharine E Harding, Emma C Tallantyre, Neil P Robertson
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 30, 2026
A framework for blood biomarker discovery in MS
Emma C Tallantyre, Sean Apap Mangion, Charlotte E Teunissen
Multiple Sclerosis and Related Disorders
|
January 23, 2022
Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate
Callum H Wood, Neil P Robertson, Zin Min Htet, et al.
Journal of Neurology
|
May 22, 2025
Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis
Laura Davies, Rasheed Shehadeh, W John Watkins, et al.
Archives of Neurology
|
August 12, 2009
Atypical progressive multifocal leukoencephalopathy associated with an unusual JC polyomavirus mutation
Emma C Tallantyre, Simon M L Paine, Colin P Sharp, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 46) with videos related to
Sort By:
Page
of 5
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 29, 2022
Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: No
Emma C Tallantyre
Journal of Neurology
|
November 2, 2018
Nerve sheath tumours
James A Robertson, Emma C Tallantyre
Practical Neurology
|
May 8, 2021
MRI: how to understand it
Claire Louise MacIver, Sian Ebden, Emma C Tallantyre
Current Opinion in Allergy and Clinical Immunology
|
October 10, 2018
Secondary antibody deficiency in neurology
Emma C Tallantyre, Neil P Robertson, Stephen Jolles
Practical Neurology
|
November 13, 2015
How to run a multiple sclerosis relapse clinic
Emma C Tallantyre, Mark Wardle, Neil P Robertson
JAMA Neurology
|
October 15, 2019
Cautious Interpretation of Observational Data-Reply
Katharine E Harding, Emma C Tallantyre, Neil P Robertson
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 30, 2026
A framework for blood biomarker discovery in MS
Emma C Tallantyre, Sean Apap Mangion, Charlotte E Teunissen
Multiple Sclerosis and Related Disorders
|
January 23, 2022
Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate
Callum H Wood, Neil P Robertson, Zin Min Htet, et al.
Journal of Neurology
|
May 22, 2025
Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis
Laura Davies, Rasheed Shehadeh, W John Watkins, et al.
Archives of Neurology
|
August 12, 2009
Atypical progressive multifocal leukoencephalopathy associated with an unusual JC polyomavirus mutation
Emma C Tallantyre, Simon M L Paine, Colin P Sharp, et al.
Page
of 5